The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2020 | Long-term follow-up of venetoclax in CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term follow-up fo clinical trials versus real-world data concerning the use of venetoclax in patients with chronic lymphocytic leukemia (CLL), including long-term safety and efficacy data, as well as clinical factors that may predict response such as minimal residual disease and genetic aberrations. Dr Davids also discusses real-world data of venetoclax in CLL presented at ESH CLL this year and highlights similarities between real-world responses and responses seen within clinical trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
